Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 2.13M | 1.41M | 1.24M | 1.41M | 124.53K |
Gross Profit | 1.36M | 793.61K | 619.52K | 670.75K | 50.09K |
EBITDA | 352.39K | -91.29K | -434.60K | -466.20K | -296.40K |
Net Income | -259.24K | -468.36K | -1.43M | -1.02M | -337.07K |
Balance Sheet | |||||
Total Assets | 1.80M | 1.68M | 1.96M | 2.21M | 297.86K |
Cash, Cash Equivalents and Short-Term Investments | 157.17K | 51.58K | 178.69K | 286.86K | 94.34K |
Total Debt | 1.72M | 1.78M | 1.68M | 1.30M | 631.00K |
Total Liabilities | 2.41M | 2.06M | 1.88M | 1.38M | 906.19K |
Stockholders Equity | -607.76K | -375.62K | 76.25K | 824.07K | -608.33K |
Cash Flow | |||||
Free Cash Flow | 142.44K | -159.63K | -388.11K | -509.31K | -197.26K |
Operating Cash Flow | 142.44K | -159.63K | -350.99K | -354.74K | -165.56K |
Investing Cash Flow | 0.00 | 0.00 | -37.12K | -154.57K | -31.70K |
Financing Cash Flow | -36.85K | 32.52K | 279.95K | 701.82K | 268.02K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
52 Neutral | $7.37B | -0.04 | -63.81% | 2.59% | 16.40% | <0.01% | |
47 Neutral | $2.26M | ― | ― | 51.31% | 51.90% | ||
45 Neutral | $6.02M | ― | -800.00% | ― | -35.03% | 57.39% | |
― | $4.59M | ― | -129.48% | ― | ― | ― | |
43 Neutral | $3.90M | ― | -218.77% | ― | -33.67% | 91.72% | |
39 Underperform | $3.21M | ― | -679.99% | ― | 55.17% | 40.47% | |
29 Underperform | $2.35M | ― | -200.56% | ― | ― | 81.35% |
On February 26, 2025, QHSLab, Inc. announced its engagement with Hayden IR to launch a comprehensive investor relations program aimed at raising visibility and strengthening relationships with the investment community. This strategic move follows significant advancements by QHSLab in expanding its digital health solutions and provider network, positioning the company to capitalize on market opportunities and effectively communicate its strategy and achievements to a broader investor audience.
On February 18, 2025, QHSLab, Inc. announced its unaudited financial results for the fourth quarter and fiscal year of 2024, revealing significant achievements including record revenue growth and positive net income. With a 98% revenue increase in Q4 2024 compared to the same quarter in 2023, the company marked its first profitable year, demonstrating strong financial momentum and resilience despite seasonal challenges. These results reflect the successful execution of strategic initiatives and operational efficiencies, reinforcing QHSLab’s commitment to sustainable profitability and long-term financial stability.
On February 11, 2025, QHSLab, Inc. announced a strategic co-marketing partnership with Town Total Compounding aimed at expanding market opportunities and enhancing patient care through integrated digital health and pharmacy solutions. This partnership will introduce QHSLab’s Integrated Service Program to over 200 primary care practices, aligning digital assessments with personalized prescription therapies, thus driving organic growth without equity dilution. By combining QHSLab’s digital technology with Town Total’s expertise in patient-specific compounding, the initiative aims to enhance provider engagement and improve patient outcomes, reflecting a scalable and non-dilutive growth strategy.